Nestle To Become No. 1 In China's Infant Formula Market Following Pfizer Nutrition Acquisition
This article was originally published in PharmAsia News
Executive Summary
With roughly 60% of Pfizer Nutrition sales coming from Asia, and 47% of that from China, Nestle slips into No. 1 spot in China’s infant formula market.
You may also be interested in...
Pfizer Sells Nutrition Portfolio To Nestle For Nearly $12B
Pfizer’s price of $11.85 billion for selling its pediatric nutritionals business to Nestle came in at the upper end of what most analysts expected. It plans to use the cash it expects to receive – nearly $9 billion – mostly for share repurchases and ‘”tuck-in” M&A.
More Barriers To Entry For M&A In China? Novartis Case Provides Some Clarity
HONG KONG - Much awaited regulations on how China will review inbound mergers and acquisitions in light of national security and competition suggest long waits for pending and future deals and new barriers to entry, say some business groups
Pfizer Nutrition Continues Launches Despite Divestment Possibility
Pfizer remains active in its international nutritionals business with the launch of an expanded line of pediatric products, even as the company considers divesting the nutrition unit.